

# **Resistin and its Relation to Inflammation and Insulin Resistance in Morbidly Obese**

## ***Thesis***

Submitted for the partial fulfillment of Master  
Degree

In Clinical and Chemical Pathology

***BY***

**Noha Mohamed Abd El- Monem Mohamed**

M.B.B.ch Faculty of Medicine - Zagazig University

Supervised by

**Professor/ Randa Abd El-Wahab Reda  
Mabrouk**

*Professor of Clinical and Chemical Pathology  
Faculty of Medicine – Ain Shams University*

**Doctor/Nesrine Aly Mohamed Omar**

*Lecturer of Clinical and Chemical Pathology  
Faculty of Medicine – Ain Shams University*

Faculty of Medicine  
Ain Shams University  
2013

## ***Acknowledgement***

***First of all thanks to Allah who helped me to do this work.***

*I would like to express my sincere appreciation and gratitude to **Prof. Dr. Randa Abd El-Wahab Reda Mabrouk** Professor of Clinical and Chemical Pathology, Faculty of Medicine , Ain Shams University for her generous supervision and kind guidance to make the realization of this work much easy.*

*I am deeply grateful to **Dr. Nesrine Aly Mohamed Omar**, Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University for her guidance and supervision.*

# **CONTENTS**

|                                           |            |
|-------------------------------------------|------------|
| <b>-LIST OF TABLES .....</b>              | <b>I</b>   |
| <b>-LIST OF FIGURES.....</b>              | <b>II</b>  |
| <b>-LIST OF ABBREVIATIONS.....</b>        | <b>III</b> |
| <b>-INTRODUCTION AND AIM OF WORK.....</b> | <b>1</b>   |
| <b>-REVIEW OF LITERATURE</b>              |            |
| I-OBESITY .....                           | 5          |
| II- NORMAL METABOLIC HOMEOSTASIS.....     | 31         |
| III- RESISTIN AND METABOLIC SYNDROME..... | 42         |
| <b>-PATIENTS AND METHODS.....</b>         | <b>65</b>  |
| <b>-RESULTS.....</b>                      | <b>75</b>  |
| <b>-DISCUSSION.....</b>                   | <b>85</b>  |
| <b>-SUMMARY AND CONCLUSION.....</b>       | <b>91</b>  |
| <b>-REFERENCES.....</b>                   | <b>95</b>  |
| <b>-ARABIC SUMMARY</b>                    |            |

## **LIST OF TABLES**

| <b>Table</b>     | <b>Title</b>                                                                                             | <b>Page</b> |
|------------------|----------------------------------------------------------------------------------------------------------|-------------|
| <b>Table (1)</b> | Classification of adult obesity.                                                                         | <b>6</b>    |
| <b>Table (2)</b> | Criteria for Diagnosis of the Metabolic Syndrome.                                                        | <b>13</b>   |
| <b>Table (3)</b> | Comparison between cases and controls as regards general data.                                           | <b>77</b>   |
| <b>Table (4)</b> | Comparison between cases and controls as regards anthropometric data.                                    | <b>78</b>   |
| <b>Table (5)</b> | Comparison between cases and controls as regards laboratory data.                                        | <b>79</b>   |
| <b>Table (6)</b> | Comparison between cases and controls as regards resistin & hs-CRP.                                      | <b>80</b>   |
| <b>Table (7)</b> | Correlations between resistin and hs-CRP, HOMA, insulin, FBS, BMI and lipid profile (IN OBESE DIABETIC). | <b>81</b>   |
| <b>Table (8)</b> | Correlations between hs-CRP and resistin, HOMA, insulin, FBS, BMI and lipid profile (IN OBESE DIABETIC). | <b>82</b>   |

|                  |                                                                                                              |           |
|------------------|--------------------------------------------------------------------------------------------------------------|-----------|
| <b>Table (9)</b> | Correlations between resistin and hs-CRP, HOMA, insulin, FBS, BMI and lipid profile (IN OBESE NON DIABETIC). | <b>82</b> |
|------------------|--------------------------------------------------------------------------------------------------------------|-----------|

## **LIST OF Figures**

| <b>Figure</b>     | <b>Title</b>                                                                           | <b>Page</b> |
|-------------------|----------------------------------------------------------------------------------------|-------------|
| <b>Figure (1)</b> | <i>obesity and insulin resistance</i>                                                  | <b>16</b>   |
| <b>Figure (2)</b> | <i>Insulin resistance in the development of the metabolic syndrome.</i>                | <b>38</b>   |
| <b>Figure (3)</b> | <i>Structure of resistin.</i>                                                          | <b>44</b>   |
| <b>Figure (4)</b> | <i>the role of SOCS3 in insulin resistance</i>                                         | <b>54</b>   |
| <b>Figure (5)</b> | <i>the role of PTEN in the development of insulin resistance in metabolic syndrome</i> | <b>56</b>   |
| <b>Figure (6)</b> | <i>Illustrated model of adipokine– endothelial cell interaction.</i>                   | <b>62</b>   |
| <b>Figure (7)</b> | <i>Mean and SD of cases and controls As regards resistin &amp; hs-CRP.</i>             | <b>83</b>   |
| <b>Figure (8)</b> | <i>Positive correlation between serum resistin and HOMA-IR in obese diabetic.</i>      |             |



**LIST OF ABBREVIATION**

|                 |                                            |
|-----------------|--------------------------------------------|
| <b>ADSF</b>     | Adipocyte-secreted factor                  |
| <b>AgRP</b>     | Agouti-related protein                     |
| <b>Akt</b>      | A family of sereine proteases              |
| <b>AMPK</b>     | AMP-activated protein kinase               |
| <b>apoB</b>     | apolipoprotein B                           |
| <b>AT</b>       | Adipose tissue                             |
| <b>ATF-2</b>    | Activating transcriptional factor 2        |
| <b>ATP</b>      | adenosine triphosphate                     |
| <b>BMI</b>      | Body mass index                            |
| <b>CCR5</b>     | C-C chemokine receptor type 5              |
| <b>CKK</b>      | Cholecystokinin                            |
| <b>CRP</b>      | C reactive protein                         |
| <b>CTLA-4</b>   | Cytotoxic T-Lymphocyte Antigen 4           |
| <b>DCs</b>      | Dendritic cells                            |
| <b>EDHF</b>     | Endothelium-derived hyperpolarizing factor |
| <b>eNOS</b>     | Endothelial Nitric oxide synthase          |
| <b>ER</b>       | Endoplasmic reticulum                      |
| <b>ET-1</b>     | Endothelin-1                               |
| <b>FBG</b>      | Fasting blood glucose                      |
| <b>FFAs</b>     | free fatty acids                           |
| <b>FIZZ3</b>    | Found in inflammatory zone 3               |
| <b>FOXO1</b>    | Forkhead box protein O1                    |
| <b>FoxP3</b>    | Forkhead box protein 3                     |
| <b>G-6-Pase</b> | Glucose-6-phosphatase                      |
| <b>GH</b>       | Growth hormone                             |
| <b>GIP</b>      | Gastric inhibitory peptide                 |
| <b>GLP-1</b>    | Glucagon like peptide-1                    |

## *List of abbreviations*

---

|                                   |                                                   |
|-----------------------------------|---------------------------------------------------|
| <b>GLUT4</b>                      | Glucose transporter                               |
| <b>HDL</b>                        | High density lipoprotein                          |
| <b>HGF</b>                        | Hepatocyte growth factor                          |
| <b>HIF-1</b>                      | Hypoxia-inducible factor-1                        |
| <b>HOMA-IR</b>                    | Homeostatic model assesment of insulin resistance |
| <b>ICAM-1</b>                     | Intracellular adhesion molecule-1                 |
| <b>IDF</b>                        | International Diabetes Federation                 |
| <b>IFG</b>                        | Impaired fasting glucose                          |
| <b>IFN-<math>\gamma</math></b>    | Interferon- $\gamma$                              |
| <b>IGT</b>                        | Impaired glucose tolerance                        |
| <b>IKK</b>                        | Kinase inhibitor of NF-Kb                         |
| <b>IL-12</b>                      | Interleukin 12                                    |
| <b>IL-15R <math>\alpha</math></b> | Interleukin 15 receptor alpha                     |
| <b>IL-1RA</b>                     | Interleukin 1 receptor antagonist                 |
| <b>IL-6</b>                       | Interleukin 6                                     |
| <b>IR</b>                         | Insulin resistance                                |
| <b>IRF1</b>                       | Interferon regulatory factor 1                    |
| <b>IRS-1</b>                      | Insulin receptor substrate-1                      |
| <b>JNK</b>                        | c-Jun NH2-terminal kinase                         |
| <b>KATP</b>                       | ATP- sensitive potassium channels                 |
| <b>KDa</b>                        | Kilo-Dalton                                       |
| <b>LDL</b>                        | Low density lipoprotein                           |
| <b>LIF</b>                        | Leukemia inhibitor factor                         |
| <b>LPS</b>                        | Lipopolysaccharide                                |
| <b>MAPK</b>                       | Mitogen-activated protein kinase                  |
| <b>MCP-1</b>                      | Monocyte chemo-attractant protein-1               |
| <b>MIF</b>                        | Macrophage migration inhibitory factor            |
| <b>MMP</b>                        | Matrix metalloproteas                             |

## *List of abbreviations*

---

|                                |                                                          |
|--------------------------------|----------------------------------------------------------|
| <b>MS</b>                      | Metabolic syndrome                                       |
| <b>NCEP</b>                    | National Cholesterol Education Program                   |
| <b>NEFAS</b>                   | Non-esterified fatty acids                               |
| <b>NF-<math>\kappa</math>B</b> | Nuclear factor kappa beta                                |
| <b>NHLBI</b>                   | National Heart, Lung, and Blood Institute                |
| <b>NK cells</b>                | Natural killer cells                                     |
| <b>NO</b>                      | Nitric oxide                                             |
| <b>NPY</b>                     | Neuropeptide Y                                           |
| <b>ob /ob</b>                  | Mouse lacks the functional form of leptin                |
| <b>Ob gene</b>                 | Obese gene                                               |
| <b>OHS</b>                     | Obesity hypoventilation syndrome                         |
| <b>OSA</b>                     | Ostructive sleep apnea                                   |
| <b>PAI-1</b>                   | Plasminogen activator inhibitor type 1                   |
| <b>PBMC</b>                    | Peripheral blood mononuclear cells                       |
| <b>PEPCK</b>                   | phosphoenolpyruvate carboxykinase                        |
| <b>PI3K</b>                    | Phosphatidylinositol triphosphate kinase                 |
| <b>PKC-<math>\theta</math></b> | Protein kinase C- $\theta$                               |
| <b>POMC</b>                    | Pro-opiomelanocortin                                     |
| <b>PPAR<math>\gamma</math></b> | Peroxisome proliferator activated receptor gamma         |
| <b>PTEN</b>                    | Phosphatase and Tensin Homolog Deleted on Chromosome Ten |
| <b>PTX3</b>                    | Pentraxin 3                                              |
| <b>PYY</b>                     | Peptide YY                                               |
| <b>RELMs</b>                   | Resistin like molecules                                  |
| <b>RETN</b>                    | gene coding for resistin                                 |
| <b>ROS</b>                     | Reactive oxygen species                                  |
| <b>SIRS</b>                    | Systematic inflammatory response syndrome                |
| <b>SNPs</b>                    | Single-nucleotide polymorphisms                          |
| <b>SOCS-3</b>                  | Suppressor of cytokine signaling-3                       |

## *List of abbreviations*

---

|                                |                                          |
|--------------------------------|------------------------------------------|
| <b>T2DM</b>                    | Type 2 diabetes mellitus                 |
| <b>TG</b>                      | Triglycerids                             |
| <b>TGF-<math>\beta</math></b>  | Transforming growth factor-beta          |
| <b>TNF-<math>\alpha</math></b> | Tumour necrosis factor alpha             |
| <b>TRAF-3</b>                  | TNF-receptor-associated factor-3         |
| <b>TZDS</b>                    | Thiazolidinedions                        |
| <b>VCAM-1</b>                  | Vascular wall adhesion molecule-1        |
| <b>VEGF</b>                    | Vascular endothelial growth factor       |
| <b>VLDL</b>                    | Very low density lipoproteins            |
| <b>WC</b>                      | waist circumference                      |
| <b>WHR</b>                     | waist-to-hip ratio                       |
| <b><math>\alpha</math>-MSH</b> | $\alpha$ -melanocyte stimulating hormone |

### INTRODUCTION

Most attention in recent years has been devoted to the concept that obesity elicits a chronic low-grade systemic inflammatory response that results from a combination of increased insulin resistance and an increased production of inflammatory mediators by the expanding pool of adipocytes **(Rensen et al., 2009)**.

Several research studies in different population indicate that inflammation may be the link between obesity and insulin resistance **(Doumatey et al., 2010)**.

Obesity is a common risk factor for dyslipidemia, insulin resistance, type 2 diabetes, hypertension and atherosclerosis, a cluster of metabolic abnormalities included in metabolic syndrome **(Grunfy et al., 2004)**.

Numerous evidences suggest that fat tissue is viewed as an active endocrine organ with high metabolic activity **(Kershaw et al., 2004)**. Adipocytes produce and release several bioactive substances that act as true hormones responsible for the regulation of energy intake and expenditure **(Mora et al., 2002)**. The dysregulation in the production of these hormones, called adipocytokines, can contribute to the proinflammatory environment

associated with obesity (**Vendrell et al., 2004**).

Following the observation that serum concentration of the number of inflammatory markers including CRP, TNF-a, and interleukin 6 are elevated in over weight and obese individuals, obesity is now viewed as a low grade inflammatory disease (**Fantuzzi, 2005**).

Taken these data inconsideration one could argue for a role of the adipose tissue as a new member of the innate immune system (**Anderson et al., 2007**).

Among the proteins synthesized and released from adipose tissue (adiponectin, angiotensin, estradiol, IL-6, leptin and TNF-a) resistin is an adipocyte secreted hormone belonging to a cysteine – rich protein family. It is expressed in white adipose tissues in rodents and has also been found in several other tissues in human. Insulin, glucose, many cytokines and anti-diabetic thiazolidinedione are regulators of resistin gene expression. Resistin was firstly proposed to be involved in insulin resistance and type 2 diabetes mellitus. Recently, it was found to be relevant to inflammation and inflammation related diseases like atherosclerosis and arthritis (**Shanshan and Yingying, 2006**).

It was found that resistin might link obesity with insulin resistance and diabetes in mice models. However, subsequent studies in rodent models have produced disparate findings on the role of resistin in obesity and insulin resistance **(Le Lay et al., 2001)**.

In humans, while the expression of resistin in human adipocytes is very low compared with that seen in rodents and does not differ between normal, insulin-resistant or type 2 diabetic individuals, a more recent study using a large size of case suggests that the plasma resistin levels are increased in type 2 diabetes **(Engert et al., 2002)**. Genetic case-control studies have demonstrated that genetic variations in the resistin gene are associated with insulin resistance and obesity **(Rajala et al., 2003)**.

More recently; it has been shown that resistin acts on the liver and antagonizes insulin signaling; thereby increasing gluconeogenesis and hepatic glucose output **(Cho et al., 2004)**.

Therefore determination of the plasma resistin levels may be important for understanding onsets of metabolic diseases such as type 2 diabetes that is considered as a complication of obesity.

### **AIM OF THE WORK**

The aim of the present study is to determine serum concentrations of resistin in morbidly obese patients in comparison to normal weight controls. It is also designed to assess the possible relation of resistin to the high sensitivity CRP as an inflammatory marker and to insulin resistance in morbidly obese.